[HTML][HTML] Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced …
MC Heinrich, K Owzar, CL Corless… - Journal of clinical …, 2008 - ncbi.nlm.nih.gov
MC Heinrich, K Owzar, CL Corless, D Hollis, EC Borden, CDM Fletcher, CW Ryan…
Journal of clinical oncology, 2008•ncbi.nlm.nih.govCorrelation of Kinase Genotype and Clinical Outcome in the North American Intergroup
Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal
Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology
Group - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI
Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol …
Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal
Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology
Group - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI
Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol …
Abstract
Purpose
Imatinib mesylate is standard treatment for patients who have advanced gastrointestinal stromal tumor (GIST), but not all patients benefit equally. In previous studies, GIST genotype correlated with treatment outcome and optimal imatinib dosing.
ncbi.nlm.nih.gov